Vaxcyte PCVX 深 沪
等待开盘 06-30 09:30:00 美东时间
57.72
+1.200
+2.12%
华盛通- 最 高57.965
- 今 开55.70
- 成交量 275.11万股
- 最 低 55.70
- 昨 收 56.52
- 总市值 83.35亿
- 52周最高 65.00
- 市盈率 静 --
- 换手率 1.91%
- 52周最低 29.08
- 委 比 -54.01%
- 总股本 1.44亿
- 历史最高 121.055
- 量 比 0.89
- 振 幅 4.01%
- 历史最低 15.51
- 每 手 1
- 风险率 9.58%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
今天 01:35
Mizuho Securities Sticks to Its Buy Rating for Vaxcyte (PCVX)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Vaxcyte on June...
06-21 16:17
Vaxcyte President, CFO Andrew Guggenhime sells 10,000 shares for $530,000
Vaxcyte President, CFO Andrew Guggenhime sells 10,000 shares for $530,000 Vaxcyte President and CFO Andrew Guggenhime exercised stock options for 10,000 common shares at USD 5.35 on June 18, 2026. He sold 10,000 common shares at USD 53 on the same day. Directly held common shares ended at 104,395 fo
06-19 08:08
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Vaxcyte has initiated a Phase 1 trial for VAX-A1, a vaccine candidate targeting Group A Streptococcus (Group A Strep), a leading cause of bacterial infections globally with no approved vaccine. The study, conducted in 80 healthy adults, aims to evaluate safety, tolerability, and immune responses. Group A Strep causes approximately 800 million cases and over 600,000 deaths annually, highlighting the urgent need for a preventive solution. VAX-A1 is...
06-02 20:05
Vaxcyte shares are trading lower after the company reported worse-than-expected Q1 EPS results.
Vaxcyte shares are trading lower after the company reported worse-than-expected...
05-08 03:05
财报速睇 | Vaxcyte 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损3.21亿美元，同比亏损扩大127.8%
华盛资讯5月7日讯，Vaxcyte公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损3.21亿美元，同比亏损扩大127.8%。
05-07 09:38
财报速睇 | Vaxcyte 2026财年Q1营收0.00亿美元，同比增长0.0%；归母净利润亏损3.21亿美元，同比亏损扩大127.7%
华盛资讯5月7日讯，Vaxcyte公布2026财年Q1业绩，公司Q1营收0.00亿美元，同比增长0.0%，归母净利润亏损3.21亿美元，同比亏损扩大127.7%。
05-07 08:32
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte announced the completion of enrollment for their OPUS-1, OPUS-2, and OPUS-3 Phase 3 trials for VAX-31, with safety and immunogenicity data expected in late 2026 and early 2027. The VAX-31 infant Phase 2 study has also completed enrollment, with results anticipated by mid-2027. VAX-A1, a vaccine for Group A Strep, is set to begin Phase 1 trials mid-2026. The company reported $2.7 billion in cash as of March 2026, following a $601.8 million...
05-06 20:05
